Biomaterials Research · 2022 · 74 citations · 46 references
PharmacyOncologyPharmacologyChemotherapyDrug DeliveryNanoparticle Drug DeliveryCancer ImmunotherapyCancer NanomedicineDrug EncapsulationNanomaterials For Drug DeliveryNanomedicineNanoparticle FormulationsAnticancer ChemotherapyCancer NanotherapyChemotherapy-induced Immunogenic Cell DeathChitosanImmune Checkpoint Inhibitor TherapyImmunogenic Cell Death InductionOrthotopic Tumor ModelsTumor Immunogenicity
BACKGROUND: Combination of chemotherapy and immune checkpoint inhibitor therapy has greatly improved the anticancer effect on multiple malignancies. However, the efficiency on triple-negative breast cancer (TNBC) is limited, since most patients bear "cold" tumors with low tumor immunogenicity. Doxorubicin (DOX), one of the most effective chemotherapy agents, can induce immunogenic cell death (ICD) and thus initiating immune response. METHODS: In this study, to maximize the ICD effect induced by DOX, chitosan and cell-penetrating peptide (R6F3)-modified nanoparticles (PNPs) loaded with ginsenoside Rg3 (Rg3) were fabricated using the self-assembly technique, followed by co-encapsulation with DOX based on thermo-sensitive hydrogel. Orthotopic tumor model and contralateral tumor model were established to observe the antitumor efficacy of the thermo-sensitive hydrogel combined with anti-PD-L1 immunotherapy, besides, the biocompatibility was also evaluated by histopathological. RESULTS: Rg3-PNPs strengthened the immunogenic cell death (ICD) effect induced by DOX. Moreover, the hydrogel co-loading Rg3-PNPs and DOX provoked stronger immune response in originally nonimmunogenic 4T1 tumors than DOX monotherapy. Following combination with PD-L1 blocking, substantial antitumor effect was achieved due to the recruitment of memory T cells and the decline of adaptive PD-L1 enrichment. CONCLUSION: The hydrogel encapsulating DOX and highly permeable Rg3-PNPs provided an efficient strategy for remodeling immunosuppressive tumor microenvironment and converting immune "cold" 4T1 into "hot" tumors.
46
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
David A. Reardon, Alba A. Brandes, Antonio Omuro et al. · JAMA Oncology · 2020 · 1.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
Wouter Scheper, Sander Kelderman, Lorenzo F. Fanchi et al. · Nature Medicine · 2018 · 579 citations · Full text
Medicine, Immunology, Oncology +16